{
  "source": "PA-Med-Nec-Duopa.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2051-11\nProgram Prior Authorization/Medical Necessity\nMedication Duopa™ (carbidopa/levodopa)\nP&T Approval Date 7/2015, 9/2016, 9/2017, 9/2018, 9/2019, 9/2020, 9/2021, 9/2022,\n8/2023, 8/2024\nEffective Date 11/1/2024\n1. Background:\nDuopa (carbidopa/levodopa) enteral suspension is indicated for the treatment of motor\nfluctuations in patients with advanced Parkinson’s disease. Duopa should be administered\ncontinuously via an infusion pump over 16 hours through a procedurally-placed tube. Duopa\nmay be administered through a naso-jejunal (NJ) tube for a short period of time until a\ngastrostomy tube can be placed.\n2. Coverage Criteria a:\nA. Initial Authorization\n1. Duopa will be approved based on all of the following criteria:\na. Diagnosis of advanced Parkinson’s Disease\n-AND-\nb. Patient experiences a wearing “off” phenomenon that cannot be managed by\nincreasing the dose of oral levodopa\n-AND-\nc. Has undergone or has planned placement of a procedurally placed tube\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Duopa will be approved based on the following criterion:\na. Documentation of positive clinical response to Duopa therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n©2024 UnitedHealthcare Services Inc.\n1\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n4. References:\n1. Duopa [package insert]. North Chicago, IL: AbbVie, Inc.; March 2022.\n2. Sara Varanese, Zoe Birnbaum, Roger Rossi, and Alessandro Di Rocco, “T",
    "ies by program and/or therapeutic class.\n4. References:\n1. Duopa [package insert]. North Chicago, IL: AbbVie, Inc.; March 2022.\n2. Sara Varanese, Zoe Birnbaum, Roger Rossi, and Alessandro Di Rocco, “Treatment of Advanced\nParkinson's Disease,” Parkinson’s Disease, vol. 2010, Article ID 480260, 9 pages, 2010.\ndoi:10.4061/2010/480260.\n3. International Parkinson and Movement Disorder Society Evidence-Based Medicine Review:\nUpdate on Treatments for the Motor Symptoms of Parkinson’s Disease. Movement Disorders.\n2018.\nProgram Prior Authorization/Medical Necessity - Duopa\nChange Control\nDate Change\n7/2015 New program.\n8/2016 Administrative change to fix typo\n9/2016 Annual Review. Updated references.\n9/2017 Annual Review. Updated background and references.\n9/2018 Annual Review. Updated references.\n9/2019 Annual review. Updated references.\n9/2020 Annual review. Updated references.\n9/2021 Annual review. No changes.\n9/2022 Annual review. Updated references.\n8/2023 Annual review. No changes.\n8/2024 Annual review. No changes.\n©2024 UnitedHealthcare Services Inc.\n2"
  ]
}